ConTIPI Medical and EVERSANA have announced the U.S. commercial launch of ProVate, a new non-surgical device for women experiencing pelvic organ prolapse (POP).
ProVate, a ready-to-use, disposable device for patients’ at-home use, is now available for physicians across the U.S. to prescribe. It is inserted vaginally in small dimensions within a disposable applicator, very similar to the concept of the menstrual tampon applicator, empowering women to take control of their medical condition. The device is available in six sizes and may be used for up to seven days. It also may be removed at any time prior, with just a pull on a string, for disposal.
“Today marks a significant milestone in women’s health in the United States as we are thrilled to see that ProVate is now available for physicians to prescribe for patients with pelvic organ prolapse,” said Dr. Elan Ziv, MD, OBGYN, Urogynecologist, CEO & Medical Director with ConTIPI Medical.
ConTIPI Medical, based in Israel’s Caesarea Industrial Park, focuses on developing non-surgical and disposable vaginal solutions for women with various pelvic floor disorders. The company’s previous device for stress urinary incontinence, the Impressa device, was acquired by Kimberly Clark Wordwide.
